Pages that link to "Q36720991"
Jump to navigation
Jump to search
The following pages link to Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector (Q36720991):
Displaying 50 items.
- Design and pre-clinical evaluation of a universal HIV-1 vaccine (Q21092234) (← links)
- Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine (Q21134724) (← links)
- A brief history of the global effort to develop a preventive HIV vaccine (Q26851165) (← links)
- Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines (Q27013568) (← links)
- Synthetic DNA vaccine strategies against persistent viral infections (Q27016078) (← links)
- Single-Dose Mucosal Immunization with a Candidate Universal Influenza Vaccine Provides Rapid Protection from Virulent H5N1, H3N2 and H1N1 Viruses (Q27318575) (← links)
- Cryo-EM structures of two bovine adenovirus type 3 intermediates (Q27689046) (← links)
- Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults (Q28740321) (← links)
- A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204) (Q28741673) (← links)
- Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses (Q28749120) (← links)
- Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa (Q28749224) (← links)
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial (Q28972526) (← links)
- Production of adenovirus vectors and their use as a delivery system for influenza vaccines (Q30226988) (← links)
- Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target (Q30227194) (← links)
- Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus (Q30229074) (← links)
- New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice. (Q30365380) (← links)
- Phase 1 study of pandemic H1 DNA vaccine in healthy adults (Q30373824) (← links)
- Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine. (Q30378897) (← links)
- Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1). (Q30379200) (← links)
- Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge. (Q30381722) (← links)
- Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. (Q30382097) (← links)
- Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications (Q30410411) (← links)
- Vaccine design for CD8 T lymphocyte responses (Q30411492) (← links)
- Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform (Q30422006) (← links)
- Human immunodeficiency virus vaccine trials (Q30424366) (← links)
- Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine (Q30578618) (← links)
- Full genome sequence analysis of a novel adenovirus of rhesus macaque origin indicates a new simian adenovirus type and species (Q30881414) (← links)
- Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors (Q33380283) (← links)
- Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization (Q33558605) (← links)
- Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates (Q33586992) (← links)
- Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors (Q33601808) (← links)
- A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). (Q33611719) (← links)
- Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites (Q33614461) (← links)
- HIV-1 vaccine development after STEP. (Q33642318) (← links)
- Novel directions in HIV-1 vaccines revealed from clinical trials (Q33645528) (← links)
- Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge (Q33676444) (← links)
- Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in China (Q33733003) (← links)
- Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054) (Q33737476) (← links)
- Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate (Q33749950) (← links)
- Prime-boost vaccination using chemokine-fused gp120 DNA and HIV envelope peptides activates both immediate and long-term memory cellular responses in rhesus macaques (Q33829574) (← links)
- Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles (Q33839468) (← links)
- New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model (Q33868760) (← links)
- Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice (Q33896435) (← links)
- Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses (Q33999615) (← links)
- Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial (Q34023588) (← links)
- The influence of delivery vectors on HIV vaccine efficacy (Q34077543) (← links)
- First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002) (Q34209026) (← links)
- Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses (Q34229968) (← links)
- Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial (Q34263835) (← links)
- The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert (Q34289823) (← links)